Abstract
Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphonates in addition to their role in inhibiting osteoclast mediated bone resorption. Both preclinical and clinical evidence of a role for bisphosphonates in the treatment and prevention of bone metastases secondary to prostate cancer is assessed.
MeSH terms
-
Adenocarcinoma / blood supply
-
Adenocarcinoma / complications
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / physiopathology
-
Adenocarcinoma / secondary*
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Apoptosis / drug effects
-
Bone Density / drug effects
-
Bone Neoplasms / blood supply
-
Bone Neoplasms / complications
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / physiopathology
-
Bone Neoplasms / secondary*
-
Bone Resorption / drug therapy*
-
Calcium / metabolism
-
Diphosphonates / pharmacology
-
Diphosphonates / therapeutic use*
-
Disease Progression
-
Homeostasis
-
Humans
-
Male
-
Neovascularization, Pathologic / drug therapy
-
Osteoclasts / drug effects
-
Osteolysis / drug therapy
-
Osteolysis / etiology
-
Osteolysis / prevention & control
-
Osteoporosis / drug therapy
-
Osteoporosis / etiology
-
Osteoporosis / prevention & control
-
Palliative Care
-
Prostatic Neoplasms / pathology*
-
Randomized Controlled Trials as Topic
-
Rats
Substances
-
Angiogenesis Inhibitors
-
Diphosphonates
-
Calcium